Latest Safety News

Livium Ltd has solidified its position in the clean energy recycling sector with new contracts, a key patent, and a $4.5 million capital raise, setting the stage for accelerated growth in lithium-ion battery and rare earth element recycling.

Noxopharm has successfully completed dosing in its HERACLES clinical trial for SOF-SKN™, demonstrating strong safety and tolerability. The company also secured a new overseas partnership and its first US patent for the Sofra platform.

Beetaloo Energy has secured key regulatory approvals and approved the Final Investment Decision for its Carpentaria Pilot Project, setting the stage for first gas sales from EP187 in late 2026.

Entropy Neurodynamics has successfully enrolled and dosed the first patient in its pioneering clinical trial of TRP-8803, an intravenous psilocin formulation targeting Binge Eating Disorder, while securing $6.1 million in new funding to accelerate development.

Percheron Therapeutics has reported encouraging safety and efficacy signals from its HMBD-002 phase I trial, and outlined an innovative modular phase II trial design targeting multiple cancers in 2026.

Zoono Group has landed its first commercial orders from three new packaging partners, marking a key milestone in its fresh food shelf-life extension strategy. The company reports NZ$551,000 cash on hand as it navigates growth and funding options.

Jupiter Mines reported a modest rise in manganese production and sales for Q2 FY2026, alongside lower production costs. However, earnings were dented by foreign exchange losses amid a stronger South African Rand.

Etherstack has reported a record-breaking 70% revenue increase in FY25, driven by major contracts and strong cashflow, and is poised for further robust growth in FY26.

Orion Minerals is finalising a major financing and offtake agreement with Glencore, advancing its transition to a mining company with first copper and zinc concentrate expected by late 2026.

Amplia Therapeutics reports encouraging clinical progress for its pancreatic cancer drug narmafotinib, with a 35% confirmed response rate in the ACCENT trial and FDA support for dose optimisation. The company also uplisted to the US OTCQB market and secured a key patent extending protection to 2040.

Lotus Resources reports steady progress at its Kayelekera uranium mine despite supply challenges, while its Letlhakane project shows promising metallurgical advances. The company targets full production and first shipments in the second quarter of 2026.

Murray Cod Australia Ltd reported a robust 61% increase in sales volume and secured key certifications in Q2 FY26, while navigating operational challenges and expanding its distribution footprint.